ArticleInternational journal of clinical and experimental medicine2014
Current evidence on the relationship between rs1256049 polymorphism in estrogen receptor-β gene and cancer risk.
Article in International journal of clinical and experimental medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 5 citations in OpenAlex.
- In Silico Characterization of PathogenicGenes · 2025Article
- Article
- Association between polymorphisms in sex hormones synthesis and metabolism and prostate cancer aggressiveness.PloS one · 2017Article
- Current evidence on the relationship between two common polymorphisms in NPAS2 gene and cancer risk.International journal of clinical and experimental medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies have suggested that estrogen receptor-β (ESR2) rs1256049 polymorphism is associated with the susceptibility of cancer. However, the results are inconsistent. We performed a meta-analysis to evaluate the association between the rs1256049 polymorphism and cancer risk. PubMed, ISI Web of Knowledge, and Chinese National Knowledge Infrastructure (CNKI), were searched for eligible studies. The odds ratios (ORs) with 95% confidence interval (CI) were used to assess the strength of association. 22 studies including 22,994 cases and 30,514 controls were identified. There was no significant association between rs1256049 and cancer risk in the overall population. Stratified analysis by ethnicity revealed that the rs1256049 polymorphism was associated with cancer risk in Caucasians (A vs. G: OR = 1.09, 95% CI = 1.01-1.16; GA vs. GG: OR = 1.10, 95% CI = 1.02-1.18; AA+GA vs. GG: OR = 1.09, 95% CI = 1.02-1.17), but not in Asians. Further subgroup analysis by cancer type indicated that the rs1256049 polymorphism may contribute to prostate cancer risk (AA vs. GG: OR = 1.41, 95% CI = 1.02-1.96; AA vs. GG+GA: OR = 1.52, 95% CI = 1.10-2.10), whereas negative results were obtained for breast cancer in any genetic model. This meta-analysis suggested that the ESR2 rs1256049 polymorphism is a candidate gene polymorphism for cancer susceptibility in Caucasians, especially in prostate cancer.
Indexed as
Identifiers
25664002PMC4307449W2400482332What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.